We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Advanced Oncotherapy Plc | LSE:AVO | London | Ordinary Share | GB00BD6SX109 | ORD 25P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.925 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | 0 | -29.49M | -0.0549 | -0.35 | 10.32M |
From Apr 2019 to Apr 2024
TIDMAVO
RNS Number : 2935J
Advanced Oncotherapy PLC
09 April 2020
9 April 2020
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Further re Subscription and Issue of Equity in lieu of fees
Further to the announcement made earlier today, Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that several directors have subscribed
for, in aggregate, 760,000 Subscription Shares at the Issue Price as part of the Subscription.
Details of the participation by certain directors in the Subscription is set out below.
In addition, a number of the Directors have agreed to receive shares in lieu of salaries, fees and bonuses owed, details of which are set out below. This will result in the issue of 825,944 new ordinary shares ("New Ordinary Shares") at the Issue Price.
Hot Features
Premium
Director Number of Subscription Number of New Ordinary
Shares Shares
Michael Sinclair (Executive
Chairman) 400,000 265,944
----------------------- -----------------------
Enrico Vanni (Non-Executive
Director) 300,000 120,000
----------------------- -----------------------
Gabriel Urwitz (Non-Executive 60,000 -
Director)
----------------------- -----------------------
Stephen Myers (Executive
Director) - 200,000
----------------------- -----------------------
Nick Plowman (Non-Executive
Director) - 120,000
----------------------- -----------------------
Hans Von Celsing (Non-Executive
Director) - 120,000
----------------------- -----------------------
Further, a number of senior management have agreed to receive shares in lieu of bonuses owed. This will result in the additional issue of 65,542 New Ordinary Shares at the Issue Price.
The definitions that apply throughout this announcement are as set out in the announcement made earlier today.
Admission and Total Voting Rights
Application will be made for the New Ordinary Shares to be admitted to trading on AIM and it is expected that admission will take place on or around 15 May 2020 ("Admission").
Upon Admission, the Company's enlarged issued share capital will comprise 305,644,992 Ordinary Shares, with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares in the Company with voting rights will be 305,644,992.
The aforementioned figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Further details and the information required in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014 are set out at the end of this announcement.
-S -
Advanced Oncotherapy plc www.avoplc.com Dr. Michael Sinclair, Executive Tel: +44 (0) 20 3617 8728 Chairman Nicolas Serandour, CEO Allenby Capital Limited (Nomad & Broker) Nick Athanas / Liz Kirchner / Tel: +44 (0) 20 3328 5656 Nicholas Chambers FTI Consulting (Financial PR advancedoncotherapy@fticonsulting.com & IR) Simon Conway / Rob Winder Tel: +44 (0) 20 3727 1000
Notes for Editors
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 Details of the person discharging managerial responsibilities
a) Name PDMRs: Michael Sinclair Executive Chairman
Enrico Vanni Non-Executive Director
-----------------------
Gabriel Urwitz Non-Executive Director
-----------------------
----------------------------- ---------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status See 1a) above
----------------------------- ---------------------------------------------
b) Initial notification Initial notification
/Amendment
----------------------------- ---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name Advanced Oncotherapy plc
----------------------------- ---------------------------------------------
b) LEI 213800LUDHZOG3YT6C82
----------------------------- ---------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----------------------------------------------------------------------------
a) Description of the financial Ordinary shares of 25p each in
instrument, type of Advanced Oncotherapy plc
instrument Identification code (ISIN) for
Identification code Advanced Oncotherapy plc ordinary
shares: GB00BD6SX109
----------------------------- ---------------------------------------------
b) Nature of the transaction Participation in a fundraise
----------------------------- ---------------------------------------------
c) Price(s) and volume(s) Price: 25p
Volumes:
Michael Sinclair 400,000
Enrico Vanni 300,000
--------
Gabriel Urwitz 60,000
--------
----------------------------- ---------------------------------------------
d) Aggregated information n/a
- Aggregated volume
- Price
----------------------------- ---------------------------------------------
e) Date of the transaction 9 April 2020
----------------------------- ---------------------------------------------
f) Place of the transaction Outside a Trading Venue
----------------------------- ---------------------------------------------
1 Details of the person discharging managerial responsibilities
a) Name PDMRs: Michael Sinclair Executive Chairman
Enrico Vanni Non-Executive Director
-----------------------
Gabriel Urwitz Non-Executive Director
-----------------------
Nick Plowman Non-Executive Director
-----------------------
Hans Von Celsing Non-Executive Director
-----------------------
Stephen Myers Executive Director
-----------------------
----------------------------- ---------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status See 1a) above
----------------------------- ---------------------------------------------
b) Initial notification Initial notification
/Amendment
----------------------------- ---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name Advanced Oncotherapy plc
----------------------------- ---------------------------------------------
b) LEI 213800LUDHZOG3YT6C82
----------------------------- ---------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----------------------------------------------------------------------------
a) Description of the financial Ordinary shares of 25p each in
instrument, type of Advanced Oncotherapy plc
instrument Identification code (ISIN) for
Identification code Advanced Oncotherapy plc ordinary
shares: GB00BD6SX109
----------------------------- ---------------------------------------------
b) Nature of the transaction Issue of ordinary shares in consideration
of payment of fees/bonuses
----------------------------- ---------------------------------------------
c) Price(s) and volume(s) Price: 25p
Volumes:
Michael Sinclair 265,944
Enrico Vanni 120,000
--------
Stephen Myers 200,000
--------
Nick Plowman 120,000
--------
Hans Von Celsing 120,000
--------
----------------------------- ---------------------------------------------
d) Aggregated information n/a
- Aggregated volume
- Price
----------------------------- ---------------------------------------------
e) Date of the transaction 9 April 2020
----------------------------- ---------------------------------------------
f) Place of the transaction Outside a Trading Venue
----------------------------- ---------------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
FURSSWEEAESSEIL
(END) Dow Jones Newswires
April 09, 2020 02:30 ET (06:30 GMT)
1 Year Advanced Oncotherapy Chart |
1 Month Advanced Oncotherapy Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
